PYXS — Pyxis Oncology, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1782223 ·
Last close
$2.86
Market Cap
$238.55M
52W High
$5.55
52W Low
$1.03
ADV30
829,167
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -25,990,000 -25,346,000 54,922,000 18,855,000 43,482,000
Mar 2026 — — — — — — —
Dec 2025 11,038,000 8,650,000 -18,295,000 -18,106,000 91,520,000 15,422,000 38,112,000
Sep 2025 0 0 -23,461,000 -22,003,000 105,604,000 8,919,000 36,825,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-66,967,000
Investing CF
$59,405,000
Financing CF
$569,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-466,449,000
Inventory
—
Receivables
$700,000
ST Investments
$35,252,000
EBIT TTM
$-85,866,000
Pretax Income TTM
$-80,349,000
Interest Exp TTM
—
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$11,038,000
EBITDA
$-85,526,000
Free Cash Flow
$-23,186,750
Enterprise Value
$252,575,840
Total Cash
$32,996,000
Total Debt
$17,832,000
Shares Out
83,408,050
Trailing EPS
$-1.40
Book Value
$0.18
ROE
-179.1%
ROA
-63.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 13,858,000 -84,420,000 -79,621,000 91,520,000 38,112,000 53,408,000 -63,502,000
Dec 2024 16,146,000 -68,496,000 -77,331,000 157,181,000 36,430,000 120,751,000 -57,672,000
Dec 2023 0 -82,196,000 -73,790,000 173,726,000 48,022,000 125,704,000 -70,709,000
Dec 2022 0 -123,481,000 -120,717,000 211,379,000 50,555,000 160,824,000 -89,335,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.13

Max Pain — expiry 2026-10-16

max pain strike: $2.50 · spot: $2.84 · call oi: 4,079 · put oi: 338
Expected Move to 2026-10-16: ±$0.75 (26.41%) — implied range $2.09 – $3.59 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MGNX MACROGENICS INC $238.24M $3.74 —
TRDA Entrada Therapeutics, Inc. $239.85M $6.16 —
SION Sionna Therapeutics, Inc. $236.14M $5.23 —
LYEL Lyell Immunopharma, Inc. $241.38M $9.85 —
PRQR ProQR Therapeutics N.V. $232.85M $1.65 —

News headlines (Yahoo Finance, 1h cache)

Pyxis Oncology shares fall 7% despite updated MICVO trial results
2026-09-09 14:08 · Yahoo
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+
2026-09-09 11:00 · Yahoo
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcin
2026-09-08 20:01 · Yahoo
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
2026-09-08 11:30 · Yahoo
Pyxis Oncology to Participate in Upcoming Investor Conferences
2026-09-01 11:30 · Yahoo
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
2026-08-13 11:00 · Yahoo
Pyxis Oncology Secures Up to $114 Million Private Placement
2026-06-30 14:30 · Yahoo
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
2026-05-14 11:00 · Yahoo
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
2026-05-07 20:05 · Yahoo
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
2026-04-17 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.